Nemdx Assays
a range of assays designed to empower pharmaceutical companies, labs and researchers with the insights needed for groundbreaking discoveries. Our assays cover a spectrum of applications, from neurodegenerative diseases to cancer mutations and bacterial identification with an unparalleled capacity to detect and measure a diverse array of compounds, spanning from minuscule molecules to substantial biomolecules such as proteins, peptides, toxins, cancer mutations, bacteria in blood, and even tumor samples.
Nemdx Assays:
A new standard for Researchers and Labs
- Ultra-low blood sample required to test targets: multiplex up to 5 targets on 5ul of sample size
- Unprecedented accuracy and reliability by design compared to stochastically derived analytes
- Cost-effective and user-friendly on widely used industry-standard plate readers, empowering lab technicians, reducing training time and maximizing cost-efficiency
- Automation and high throughput, sample versatility, scalability, innovation and novelty, collaboration potential
- Demonstrated clinical utility and remarkably swift turnaround for new targets, typically within days to weeks from conception to realization, substantially curtails both time and expenses, expediting the researcher’s journey
Current RuO Assays:
Our proprietary assays, including TDP-43, Tau, and Neurofilaments, offer quantification and activity measurements, providing essential data for disease progression tracking and therapeutic development.
Please note that these tests are currently available only to participants in Nemdx’s research activities.
We Provide
An effective partner for Pharma:
- Nemdx rational approach is designed to aid drug and biomarker developments to monitor the impact of compounds on a targeted protein, patients’ stratification and companion diagnostics
- High accuracy and precision in detecting disease markers or biomolecules
- Detection of low concentrations of biomarkers with minimal false positives or false negatives
- Quick turnaround times enable researchers to monitor patient responses to therapies and make adjustments as needed
- Low sample volume requirements to allow non-invasive or less invasive testing
- Multiplexing capabilities to provide a comprehensive view of disease status and reduce the need for multiple tests and conserve valuable patient samples
- SeamlessLY integrated into drug development pipelines with compatibility with existing laboratory equipment and workflows
- Rapidly adaptable to new biomarkers or disease indicators without requiring extensive modifications are highly desirable
- Clear clinical utility and relevance, (COMMA) offering insights into disease mechanisms, patient stratification, or therapy response prediction
- Valuable information without excessive costs
Collaborative partnerships enhance the development and validation of companion diagnostics, aligning with the pharma company’s therapeutic goals.